Heartflow, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider Trading Arrangements
During the quarter ended September 30, 2025, three of our directors or officers (as defined in Rule
16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted, modified orterminated a
“Rule 10b5-1 (c) trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as each term is
defined in Item 408(a) of Regulation S-K as follows:
On September 12, 2025, John C.M. Farquhar, our President and Chief Executive Officer, adopted a Rule
10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 427,900
shares of our common stock. The duration of the trading arrangement is until January 11, 2027, or earlier
if all transactions under the trading arrangement are completed. The trading arrangement is intended to
satisfy the affirmative defense in Rule 10b5-1(c).
On September 12, 2025, Campbell D.K. Rogers, M.D., our Chief Medical Officer, adopted a Rule 10b5-1
trading arrangement providing for the sale from time to time of an aggregate of up to 254,144 shares of
our common stock. The duration of the trading arrangement is until April 2, 2026, or earlier if all
transactions under the trading arrangement are completed. The trading arrangement is intended to satisfy
the affirmative defense in Rule 10b5-1(c).
On September 12, 2025, Julie A. Cullivan, one of ourdirectors, adopted a Rule 10b5-1 trading
arrangement providing for the sale from time to time of an aggregate of up to 17,122 shares of our
common stock. The duration of the trading arrangement is until March 27, 2026, or earlier if all
transactions under the trading arrangement are completed. The trading arrangement is intended to satisfy
the affirmative defense in Rule 10b5-1(c).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.